secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2021-10-20T23:59:59+00:00
Accession:  0001104659-21-127874
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q3 sales $10.9B (+23.4%); adj. EPS $1.40 (+42.9%); raises FY guidance
----------------------------------------------------------------------------

- GAAP diluted EPS $1.17; adjusted diluted EPS $1.40, up 42.9% vs 3Q20.
- Global COVID-19 testing sales $1.9B; total organic sales growth 22.4%.
- Full-year 2021 GAAP EPS guidance raised to $3.55-$3.65; adjusted $5.00-$5.10.
- Board declared $0.45 quarterly dividend (payable Nov. 15, 2021); 49th consecutive annual increase.
- Acquired Walk Vascular; received FDA approvals for Amplatzer Amulet, Portico TAVR, and Talisman PFO systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465921127874/0001104659-21-127874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465921127874/tm2130546d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-127874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer